From Signal to Surveillance: Assessing the Role of MicroRNAs in Cardiac Allograft Rejection

Read full text Summarise with VIRAT
Authors: L. Truby, MARYJANE A. FARR
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

heart transplant rejection surveillance; molecular diagnostics Allograft rejection after heart transplantation (HT) has historically been a source of significant morbidity and mortality in the early post-transplant period.In the era of cyclosporine-and azathioprine-based immunosuppression regimens, acute rejection occurred in as many as 80% of recipients in the first year, with the highest incidence in the first 6 months 1 .This led to standard recommendations for aggressive invasive rejection surveillance protocols for the first six to twelve months after HT -an approach that continues to be used by many transplant centers 2 .However, more recent advances in immunosuppressive agents have translated into a significant reduction in rejection events, with data from the International Society for Heart and Lung Transplantation (ISHLT) suggesting that fewer than 10-20% of recipients have a "treated rejection event" in the first post-transplant year 3 .As such, the last two decades have seen development and refinement of non-invasive molecular diagnostic platforms for rejection surveillance, evolving from gene expression profiling to the more contemporary donor-derived cell-free DNA assay.An increasing number of centers have moved away from serial endomyocardial biopsies in favor of these approaches, but without a change in frequency of assessments.The use of donor-derived cell-free DNA, despite its high negative predictive value, poses certain challenges that continue to necessitate invasive diagnostic strategies, namely the relative inability to distinguish nonspecific myocardial injury, or T and B lymphocyte clusters within the allograft (the purportedly benign "Quilty lesion"), from acute cellular (ACR) and antibody-mediated rejection (AMR).In this issue of Circulation: Heart Failure, authors from the Genomic Research Alliance for Transplantation (GRAfT) Consortium provide additional data to support the potential role of microRNAs (miRNAs) as a novel surveillance tool for allograft rejection 4 .Whether this signal can be translated into a meaningful surveillance strategy with incremental benefit beyond existing tools remains to be seen.

Fields of Study & Subjects

Transplantation: Methods and Outcomes Renal Transplantation Outcomes and Treatments Organ and Tissue Transplantation Research

Publication details

Journal / source
Circulation Heart Failure
Volume
19
Issue
5
Pages
e014207–e014207
Publication date
30 March 2026
Language
EN